The research team approached the problem from a perspective that has been reshaping the field for the past decade. Diabetic retinopathy is increasingly understood not simply as a plumbing failure of tiny blood vessels, but as a neurovascular degenerative disease in which early neuronal dysfunction, chronic metabolic stress and progressive microvascular damage reinforce one another. Within that framework, the metabolic state of endothelial cells, the thin layer of cells lining the interior of blood vessels, becomes a central question. Growing new vessels is an energetically expensive enterprise, and endothelial cells must ramp up their metabolism to proliferate, migrate and remodel tissue.

Lipocalin-2, often abbreviated LCN2, entered the picture because clinical studies had already reported elevated levels of the protein in patients with diabetic retinopathy. Elevated levels of a molecule in a disease state, however, do not by themselves prove that the molecule causes the disease; it could be a bystander, a marker of tissue stress, or even a protective response. What remained poorly defined, as the authors note in their abstract, was the functional role of LCN2 in diabetic retinal vascular pathology. Answering that question required more than correlation, and the team turned to a pair of genetically engineered mouse models designed to manipulate LCN2 with precision.

The first model was an LCN2 overexpressing mouse, designated LCN2-Tg, in which the animals carry extra copies of the gene and produce abnormally high amounts of the protein throughout life. The second was the opposite experiment: an endothelium-specific LCN2 knockout, written Lcn2-fl/fl; Cdh5-CreERT2, in which the gene is deleted selectively in endothelial cells. The Cdh5-CreERT2 system uses the cadherin-5 promoter, active almost exclusively in vascular endothelium, to drive an inducible form of the Cre recombinase enzyme, allowing researchers to remove Lcn2 from blood vessel lining cells in adult animals. This specificity matters, because LCN2 is produced by many cell types, including immune cells and epithelial tissue, and a whole-body knockout would make it impossible to attribute any vascular effect to the endothelium itself.

With these tools in hand, the researchers examined how LCN2 influences retinal vascular remodeling and endothelial function under both physiological and pathological conditions. The results were striking. Loss of LCN2 in endothelial cells suppressed both the normal, developmental expansion of retinal vessels and the pathological vessel growth that mimics what happens in diabetic retinopathy. Crucially, however, the deficiency did this while preserving vascular stability. That distinction is important from a therapeutic standpoint: an ideal treatment for retinal neovascularization would prune away the destructive, leaky vessels that characterize the disease without destabilizing the healthy vasculature that the retina depends on for oxygen and nutrients.

The mechanistic heart of the paper lies in energy metabolism. When the team looked at animals and cells with elevated LCN2, they found enhanced endothelial cell energy metabolism, and this metabolic boost went hand in hand with exacerbated pathological neovascularization. In other words, LCN2 appears to act as a metabolic enabler for endothelial cells, revving up their bioenergetic machinery so they can sustain the high demands of proliferation and migration. Sprouting new capillaries requires cells to divide rapidly, crawl through surrounding tissue, and reorganize their cytoskeletons, all of which consume large quantities of ATP and biosynthetic intermediates. By amplifying metabolic capacity, LCN2 gives pathological vessels the fuel they need to advance.

The converse experiment confirmed the logic. When LCN2 was downregulated, endothelial cells showed suppressed proliferation and migration, accompanied by a restricted metabolic capacity. The cells simply lacked the energetic headroom to mount an angiogenic response. This coupling of behavior to metabolism is consistent with a broader theme in vascular biology: endothelial cells are not passive tubes but metabolically dynamic cells whose glycolytic flux, mitochondrial activity and nutrient handling directly govern whether vessels sprout, stabilize or regress. The new study places LCN2 squarely within that regulatory circuitry, identifying it as a regulator of what the authors call endothelial metabolic competence in the diabetic retina.

Why does this matter for patients? Current treatments for proliferative diabetic retinopathy rely heavily on blocking vascular endothelial growth factor, or VEGF, either through injections of anti-VEGF antibodies into the eye or through laser photocoagulation that destroys peripheral retinal tissue to reduce oxygen demand. These approaches have transformed outcomes, but they have limitations. Anti-VEGF therapy requires repeated injections, some patients respond incompletely, and there are lingering concerns about the long-term effects of suppressing a factor that also supports neuronal and vascular health in the retina. A target that operates through a different axis, in this case cellular energy metabolism rather than growth factor signaling, could complement existing therapies or offer an alternative for patients who do not respond well to VEGF blockade.

The authors are careful about the translational implications, and appropriately so. Their conclusion is that pathological upregulation of LCN2 contributes to retinal microvascular dysfunction, and that targeting LCN2-dependent metabolic regulation may therefore represent a potential therapeutic strategy for diabetic retinopathy. That is a long road from a mouse study. Human diabetic retinopathy unfolds over years in a metabolic environment shaped by hyperglycemia, inflammation and oxidative stress, and interventions that work in genetically defined animals do not always translate. Any future therapy would need a safe way to inhibit LCN2 in the eye, whether through antibodies, small molecules or gene-based approaches, and would need to avoid interfering with the protein’s beneficial roles in innate immunity and tissue repair elsewhere in the body.

Even so, the study adds a compelling new character to the cast of molecules implicated in diabetic eye disease, and it does so with an unusually clean experimental design that combines gain-of-function and cell-type-specific loss-of-function genetics. It also reinforces a conceptual shift with implications well beyond ophthalmology: pathological angiogenesis is not just a signaling problem but a metabolic one, and the vessels that ravage the diabetic retina can be weakened by cutting their fuel supply. For the hundreds of millions of people living with diabetes worldwide, and for the growing fraction of them who will develop retinopathy as the disease progresses, a new metabolic handle on the process is a development worth watching closely.

Subject of Research: The role of lipocalin-2 in endothelial energy metabolism and pathological angiogenesis in diabetic retinopathy

Article Title: Knockdown of lipocalin 2 alleviates ocular angiogenesis in diabetic retinopathy by lowering endothelial cell energy metabolism

Article References: Mei, T., Yang, H., Zuo, H., Wu, J., Liu, K., Zhao, M., Wu, K., Song, H., Zhang, Z., Luo, S., Lai, Y., Luo, J., Zhang, F., Zuo, C., & Zhao, L. (2026). Knockdown of lipocalin 2 alleviates ocular angiogenesis in diabetic retinopathy by lowering endothelial cell energy metabolism. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03378-3

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03378-3

Keywords: diabetic retinopathy, lipocalin-2, angiogenesis, endothelial cells, energy metabolism, retinal vascular disease, knockout mouse models, neovascularization, metabolic regulation, ophthalmology, vascular biology, Cell Death Discovery

The study, published in Acta Parasitologica by a large team of researchers led by Fuzhong Fang and Zhiyi Lin of the First Affiliated Hospital of Shihezi University in Xinjiang, China, set out to answer a deceptively simple question: does hepatic alveolar echinococcosis, commonly abbreviated HAE, truly exhibit the invasive growth behavior of hepatocellular carcinoma, the most common form of primary liver cancer? To find out, the investigators collected lesional tissue samples from patients diagnosed with each condition, prepared histological slides, and systematically examined the specimens under light microscopy, comparing the two diseases across every clinically meaningful interface between lesion and host liver.

The first major finding concerns the blood vessels within the lesions, and it cuts to the heart of why HAE has been compared to cancer in the first place. Malignant tumors are master angiogenic machines: they recruit and construct dense clusters of brand-new microvessels to feed their expanding mass, a process that also provides a highway for metastasis. When the researchers examined the vascular structures embedded in HAE lesions, however, they found something fundamentally different. The vessels inside the parasitic lesions were predominantly residual vessels, pre-existing hepatic vessels that had been encased and progressively compressed by the advancing lesion rather than newly forged by an angiogenic program. In hepatocellular carcinoma samples, by contrast, clustered neovascularization predominated, confirming the aggressive, self-supplying character of the cancer.

The same logic applied to the bile ducts. Within HAE lesions, the bile ducts the team observed represented residual normal bile duct structures that had been swallowed up and enveloped by the growing parasite mass, not new ducts generated by the lesion. In hepatocellular carcinoma, only a small percentage of cases showed subtle proliferation of small bile ducts within the tumor stroma. Intriguingly, the picture was more symmetrical when it came to nerves. Perineural encasement, in which the lesion wraps around nerve trunks without breaching them, was observed in 12.6 percent of HAE cases versus 8.4 percent of HCC cases, a difference the authors report as statistically non-significant with a P value of 0.319. True neural invasion, where the process actually penetrates the nerve, occurred in 3.9 percent of HAE cases and 1.9 percent of HCC cases, also not significantly different at P equals 0.644. In this narrow sense, the parasite and the cancer do share a behavioral quirk.

The most decisive evidence emerged at the interface between lesional and hepatic tissue, the true battleground where malignant tumors declare their identity. In the HAE specimens, the fibrous capsule surrounding the lesion remained intact throughout, with no evidence of infiltration through this biological barrier. The lesion expanded outward like a slowly inflating balloon, pushing structures aside rather than chewing through them. The hepatocellular carcinoma specimens told a completely different story: cancer cell infiltration across the interface was observed in fully 80.4 percent of cases, a difference the authors report as statistically significant at P less than 0.05. HAE likewise showed no direct invasion of the hepatic parenchyma, consistent with the preservation of the liver’s fibrous septa, whereas septal disruption with direct parenchymal invasion along the sinusoidal channels was identified in 17.8 percent of the HCC cases, again a significant difference.

Vascular behavior at the interface sharpened the contrast further. The incidence of vascular compression, in which the growing lesion simply squeezes a vessel, was comparable between the two groups, occurring in 20.4 percent of HAE cases and 16.8 percent of HCC cases with a P value of 0.507. But when the researchers looked for genuine vascular invasion, malignant cells or larval tissue actually breaching the vessel wall and entering the lumen, the two diseases diverged dramatically. Vascular invasion was rare in HAE, detected in just 1.9 percent of cases, while it occurred in 31.8 percent of hepatocellular carcinoma cases, a highly significant difference. The bile ducts followed a similar pattern of benign equivalence: bile duct compression rates were not significantly different between the conditions, at 16.5 percent for HAE and 10.3 percent for HCC, and bile duct invasion was rare in both, at 1.9 percent versus 3.7 percent with a P value of 0.714.

At the outermost boundary, where lesions reached the liver’s surface, the pattern held firm. HAE lesions adjacent to the hepatic capsule were consistently covered by dense fibrous tissue, with no evidence of invasion through the capsule itself. Hepatocellular carcinoma, true to its nature, showed direct capsular invasion in 17.8 percent of cases, another statistically significant difference. Taken together, the authors argue, these findings demonstrate that from a pathological perspective, the growth pattern of hepatic alveolar echinococcosis differs markedly from the invasive growth of hepatocellular carcinoma. The parasite grows expansively, always encased within a fibrous capsule, displacing anatomy rather than destroying it. The cancer grows infiltratively, breaching every natural barrier the liver can erect and seeding its own spread through vessels, septa, and capsules.

The clinical implications of this distinction could be substantial. If HAE lesions reliably maintain an intact fibrous capsule as they expand, then the boundary between parasite and host tissue represents a genuine surgical plane, a clean theoretical line along which a scalpel can safely travel. The study’s authors explicitly state that this expansive, capsule-confined growth pattern provides a theoretical foundation for the complete surgical resection of the lesion, and it may bolster confidence in organ-preserving and capsule-based techniques such as intracapsular enucleation, approaches designed to remove the lesion while sparing as much healthy liver as possible. For a disease in which radical resection can demand removal of the majority of the liver, and in which transplantation is sometimes the only remaining option, the anatomical reassurance that the parasite respects its capsule could help more patients qualify for limited resections and better functional outcomes.

The findings also carry conceptual weight for how the medical community frames a neglected zoonotic disease. Alveolar echinococcosis remains a serious public health problem across large swaths of Central Asia, northwestern China, Siberia, and parts of Europe, with fatality rates that were historically dismal and a global burden estimated in the hundreds of thousands of disability-adjusted life years. Calling HAE a parasitic cancer has always been a useful shorthand for conveying urgency, but the new data suggest the metaphor should be used with precision: the disease behaves like a cancer in its relentless, lethal potential and its capacity for local destruction, yet it does not obey the histological grammar of malignancy. Understanding that difference, the researchers conclude, offers a new theoretical basis for optimizing clinical management strategies, and a reminder that even the most intimidating imitations in pathology can be unmasked by careful examination of the tissue itself.

Subject of Research: Histopathological differences in growth patterns between hepatic alveolar echinococcosis and hepatocellular carcinoma

Article Title: Pathological Study on Differences in Growth Patterns Between Hepatic Alveolar Echinococcosis and Hepatocellular Carcinoma

Article References: Fang, F., Lin, Z., Li, J., Jiao, F., Zhang, Y., Chen, Q., Wang, M., Xin, Z., Yao, Y., Hu, C., Zhou, J., Tian, H., Xu, N., Yue, P., Yang, Y., Makhmudova, L. B., Ali, M., Pathar, A. J., Peng, X., & Zhang, H. (2026). Pathological Study on Differences in Growth Patterns Between Hepatic Alveolar Echinococcosis and Hepatocellular Carcinoma. Acta Parasitologica, 71(5), Article 202. https://doi.org/10.1007/s11686-026-01387-x

Image Credits: AI Generated

DOI: 10.1007/s11686-026-01387-x

Keywords: hepatic alveolar echinococcosis, hepatocellular carcinoma, growth patterns, fibrous capsule, vascular invasion, neovascularization, pathology, parasitic liver disease, Echinococcus multilocularis, expansive growth, infiltrative growth, surgical resection